Cardiff Oncology Stock Plunges After Sudden Leadership Change, Narrowed Trial Focus

Core Viewpoint - Cardiff Oncology Inc. experienced a significant decline of approximately 32% in stock price following management and trial updates, indicating investor concern over leadership changes and clinical trial focus [1][9]. Management Changes - Mani Mohindru has been appointed as interim CEO, effective immediately, following the resignation of CEO Mark Erlander and CFO James Levine [1][2]. - Brigitte Lindsay has been promoted to Chief Accounting Officer to ensure financial continuity, having been with the company for over 14 years [2]. Clinical Trial Update - Cardiff Oncology provided an update on the CRDF-004 trial, which is a Phase 2 study evaluating onvansertib in combination with standard care regimens for patients with RAS-mutated metastatic colorectal cancer [3]. - The trial showed a 72.2% confirmed objective response rate in the 30 mg dose group of onvansertib with FOLFIRI/bevacizumab, compared to 43.2% in the standard care group, approaching statistical significance (p-value = 0.051) [4]. - Progression-free survival was statistically significant for the 30 mg onvansertib plus FOLFIRI/bevacizumab group (p-value = 0.048), with median progression-free survival not yet reached in the treatment groups [5]. Future Plans - Based on the trial results, the company plans to advance the 30 mg dose of onvansertib with FOLFIRI/bevacizumab into a registrational trial for first-line patients with RAS-mutated metastatic colorectal cancer, pending FDA consultation [6]. - The focus will be narrowed to onvansertib in combination with FOLFIRI, which may reduce the total addressable market in the frontline setting to 12%-20% from a previous estimate of 40%-50% [8]. Analyst Commentary - Analysts from William Blair expressed concerns regarding the abrupt management changes and the narrowed focus on onvansertib with FOLFIRI, leading to a reduction in the probability of success from 50% to 45% [8]. - Despite the concerns, William Blair maintains an Outperform rating for the stock [9].